Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Tavo + Pembrolizumab for Melanoma
Recruiting1 awardPhase 2
Lebanon, New Hampshire
This trial will study the effects of a new treatment for melanoma that has progressed after treatment with pembrolizumab or nivolumab. The new treatment, tavo, will be given intratumorally (into the tumor) and intravenously (into the vein), and will be delivered using a process called electroporation.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.